Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study.

Authors

Chih-Hsi Scott Kuo, Shigeki Umemura, Chin-Chou Wang, Shingo Matsumoto, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Hiroki Izumi, Yuji Shibata, Hibiki Udagawa, Kiyotaka Yoh, Yuri Murata, Koichi Goto, Cheng-Ta Yang

Published in

Lung Cancer (Auckland, N.Z.). Volume 17. Pages 631512. Epub Oct 13, 2026.

Abstract

Targeted therapy improves survival of oncogene-driven NSCLC. We evaluate the clinical outcome of advanced NSCLC with oncogenic drivers in LC-SCRUM-Asia Taiwanese and Japanese cohort using tiered groups of disease-driven oncogene.
Fourteen genes were reported from NGS and grouped into four tiers based on lines of approved targeted therapies in Taiwan and Japan (Tier 1: ≥ two lines; Tier 2: one line; Tier 3: not targetable; Tier 4: potentially targetable; not yet approved). Overall survival (OS) of the four-tier gene groups was analyzed in Taiwanese cohort and validated in the 8619 Japanese patients using a two-stage approach.
Three-hundred-fifty-nine patients were enrolled in Taiwanese cohort, of which 249 (69.4%) patients had a reported genomic alteration. Patients with a history of smoking (HR 0.46 [95% CI, 0.23-0.92]; p=0.031) and squamous cell carcinoma (HR 0.31 [95% CI, 0.12-0.78]; p=0.014) had a lower incidence of genomic alterations. The top five genomic alterations were EGFR (44.6%), KRAS (7.2%), ALK (3.9%), MET (3.1%) and ERBB2 (2.5%) mutations. The four-tier gene groups were significantly associated with different OS in Taiwanese patients (Log rank test p < 0.001). The adjusted OS was the longest and the shortest in patients with Tier 1 (34.5 months) and Tier 4 (16.6 months) gene groups, respectively. In Japanese cohort, a similar trend between the four-tier gene groups and OS was observed (Log rank test p < 0.001) where the Tier 1 and the Tier 4 gene groups also demonstrated the longest (42.6 months) and the shortest OS (18.9 months), respectively.
The available lines of targeted therapy impact survival in patients of advanced oncogene-driven NSCLC.

PMID:
42893218
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.